Search results
Results from the WOW.Com Content Network
Cefoperazone contains an N-methylthiotetrazole (NMTT or 1-MTT) side chain.As the antibiotic is broken down in the body, it releases free NMTT, which can cause hypoprothrombinemia (likely due to inhibition of the enzyme vitamin K epoxide reductase) and a reaction with ethanol similar to that produced by disulfiram (Antabuse effect), due to inhibition of aldehyde dehydrogenase.
Cefoperazone/sulbactam is a combination drug used as an antibiotic. It is effective for the treatment of urinary tract infections . [ 2 ] It contains cefoperazone , a β-lactam antibiotic , and sulbactam , a β-lactamase inhibitor , which helps prevent bacteria from breaking down cefoperazone.
The Indonesian Food and Drug Authority (Indonesian: Badan Pengawas Obat dan Makanan, lit. 'Food and Drug Supervisory Agency'), Badan POM/BPOM, or Indonesian FDA is a government agency of Indonesia responsible for protecting public health through the control and supervision of prescription and over-the-counter pharmaceutical drugs (medication), vaccines, biopharmaceuticals, dietary supplements ...
The combination cefoperazone/sulbactam (Sulperazon) is available in many countries but not in the United States. [4] The co-packaged combination sulbactam/durlobactam was approved for medical use in the United States in May 2023. [5]
This systemic antibiotic -related article is a stub. You can help Wikipedia by expanding it.
This subdivisions is a local level of government beneath the provincial level. However, they enjoy greater decentralisation of affairs than the provincial body, such as provision of public schools and public health facilities. They were formerly known collectively as Daerah Tingkat II (Level II Region). [14]
During Indonesian National Revolution, the civil service was divided into Republic of Indonesia government and Dutch East Indies government. The Indonesian government formed Office of Civil Servant Affairs (Indonesian: Kantor Urusan Pegawai Negeri, KUP) with Government Regulation 11/1948 on 30 May 1948 which located at Yogyakarta.
For many bacterial infections, it offers little or no advantage over ceftazidime monotherapy, due to the widespread expression of resistance mechanisms other than β-lactamase production.